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Immunology and Microbiology
Genome-Wide Identification of Chlamydia trachomatis
Antigens Associated with Trachomatous Trichiasis
Chunxue Lu,1,2 Martin J. Holland,3,4 Siqi Gong,1 Bo Peng,1,2 Robin L. Bailey,3 David W. Mabey,3
Yimou Wu,2 and Guangming Zhong1,2
PURPOSE. Chlamydia trachomatis is the leading infectious
cause of blindness. The goal of the current study was to search
for biomarkers associated with C. trachomatis–induced ocular
pathologies.
METHODS. We used a whole genome scale proteome array to
systematically profile antigen specificities of antibody respons-
es to C. trachomatis infection in individuals from trachoma-
endemic communities with or without end-stage trachoma
(trichiasis) in The Gambia.
RESULTS. When 61 trichiasis patients were compared with their
control counterparts for overall antibody reactivity with
organisms of different chlamydial species, no statistically
significant difference was found. Both groups developed
significantly higher titers of antibodies against C. trachomatis
ocular serovars A and B than ocular serovar C, genital serovar D,
or Chlamydia psittaci, whereas the titers of anti–Chlamydia
pneumoniae antibodies were the highest. When antisera from
33 trichiasis and 26 control patients (with relatively high titers
of antibodies to C. trachomatis ocular serovars) were reacted
with 908 C. trachomatis proteins, 447 antigens were recog-
nized by at least 1 of the 59 antisera, and 10 antigens by 50% or
more antisera, the latter being designated as immunodominant
antigens. More importantly, four antigens were preferentially
recognized by the trichiasis group, with antigens CT414,
CT667, and CT706 collectively reacting with 30% of trichiasis
antisera but none from the normal group, and antigen CT695
reacting with 61% of trichiasis but only 31% of normal antisera.
On the other hand, eight antigens were preferentially recog-
nized by the control group, with antigens CT019, CT117,
CT301, CT553, CT556, CT571, and CT709 together reacting
with 46% of normal antisera and none from the trichiasis group,
whereas antigen CT442 reacted with 35% of normal and 19% of
trichiasis antisera respectively.
CONCLUSIONS. The current study, by mapping immunodominant
C. trachomatis antigens and identifying antigens associated with
both ocular pathology and protection, has provided important
information for further understanding chlamydial pathogenesis
and the development of subunit vaccines. (Invest Ophthalmol
Vis Sci. 2012;53:2551–2559) DOI:10.1167/iovs.11-9212
The obligate intracellular bacterium Chlamydia trachoma-tis is the leading cause of both infectious blinding diseases1
and sexually transmitted bacterial diseases2 worldwide. Re-
peated or persistent ocular infection with C. trachomatis can
cause inflammatory pathologies in the eye, leading to
trachoma, trachomatous trichiasis, and blindness. Despite
extensive efforts in defining the role of host3–7 and bacterial
factors8–11 in ocular inflammatory pathologies, chlamydial
pathogenic mechanisms remain unclear. The main C. tracho-
matis serovars responsible for trachoma are A, B, and C,
whereas C. trachomatis serovars D to L3 mainly cause
urogenital tract infection.
To understand the molecular mechanisms of chlamydial
pathogenesis and immunity in humans, efforts have been
made to identify serological markers of Chlamydia-induced
pathologies in either the female upper genital tract or ocular
tissues. Antibodies to chlamydial heat shock protein 60
(HSP60) have been associated with Chlamydia-induced
inflammatory damage in fallopian tubes,12–14 therefore the
possibility arises that chlamydial HSP60 and host immune
responses to HSP60 may contribute to chlamydial pathoge-
nicity. There is evidence that shows that chlamydial HSP60
can directly activate macrophages to secrete inflammatory
cytokines15 and that chlamydial HSP60 can also be the target
of16,17 or promote16,18 T-cell responses; however, because of
the high degree of amino acid sequence conservation
between chlamydial and human HSP60 proteins, antibodies
against chlamydial HSP60 may cross-react with host
HSP60.19,20 A whole genome scale protein array profiling of
antigen specificities of antibody responses to C. trachomatis
urogenital infection has confirmed the association of HSP60
with tubal inflammatory damage and also identified new
serological markers, such as OmcB, which are preferentially
recognized by serum from patients with tubal factor
infertility.21 A recent study also reported high titers of
antibodies to C. trachomatis HSP60, chlamydial protease/
proteasome-like activity factor (CPAF), and CT795 in Nepalese
trachoma patients.9 In the current study, we compared the
antigen specificity profiles of antibody responses to C.
trachomatis in individuals with trichiasis and healthy controls
from trachoma-endemic communities. This has revealed a map
of the immunodominant C. trachomatis antigens in trachoma
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and has identified antigens associated with both protection
and pathology in trichiasis.
MATERIALS AND METHODS
Ethical Permission and Study Participants
The study was conducted in accordance with the tenets of the
Declaration of Helsinki. The study and its procedures were approved
by the joint Gambian Government/Medical Research Council Ethics
Committee (SCCL2006.10 and 18). Informed consent was obtained
before the enrollment of each subject. Participants were recruited from
the Western, Central, and Lower River Regions of The Gambia between
May 2006 and February 2009. Trachoma was graded using the World
Health Organization simplified grading system by a single experienced
field supervisor. Subjects with trachomatous conjunctival scarring (TS)
who also had trichiasis (TT), defined as at least one eyelash touching
the globe of the eye, were identified. For each TT case, an age, sex, and
location–matched control subject with normal eyes who was not a
member of the same family was also recruited. Participants were age
matched within 5 years (up to 45 years of age) or 10 years (participants
older than 45 years). In a standardized manner, an ocular swab from
the everted tarsal conjunctiva of each participant was collected as
described previously.5,22 A venous blood sample was requested for the
isolation of peripheral blood mononuclear cells and plasma as
described previously.23 All subjects requiring a lid margin rotation
procedure were offered unilamella tarsal rotation (Trabut) surgery free
of charge, which was carried out by Gambian National Eye Care
Programme ophthalmic nurses in regional health centers or in the
homes of the patients. All other conditions requiring treatment were
referred to regional centers for care.
Defibrination of Heparinized Plasma
Plasma was converted to serum using a previously described method.24
Briefly, a solution of 100 IU/mL of thrombin (Sigma, Poole, UK) was
prepared by addition of 1M CaCl2. Protamine sulfate was then added to
a final concentration of 5 mg/mL. Then, 10 lL of this solution was
added to 1 mL of each plasma sample. After vigorous vortex mixing,
the sample was incubated at room temperature (238C) for 1 hour
followed by centrifugation at 10,000g for 20 minutes at 48C. The
supernatant was carefully collected and the clot discarded. The
supernatant was aliquoted and frozen at -208C until used. Frozen
samples were transported between the laboratories involved in
different countries on a dry ice cold chain.
Detection of Current C. trachomatis Ocular
Infection
The AMPLICOR CT/NG test (Roche Diagnostics, Indianapolis, IN) was
used for detection of C. trachomatis in cases and controls as described
elsewhere.3 Positive and negative samples were assigned according to
the manufacturer’s instructions. Sample quality, inhibition, and
sufficiency for PCR were assessed by PCR amplification of human
mitochondrial DNA–specific sequences as described previously.3
Cell Culture and Chlamydial Infection
HeLa cells (American Type Culture Collection, Manassas, VA) were
cultured in Dulbecco’s modified Eagle’s medium (DMEM; GIBCO PRL,
Rockville, MD) with 10% fetal calf serum (FCS; GIBCO BRL) at 378C
with 5% CO2 as described previously.
14,25,26 C. trachomatis serovars A,
B, C, and D; Chlamydia psittaci 6BC; or Chlamydia pneumoniae
AR39 organisms were grown, purified, and titrated as previously
described.14,27–29 After titration, organisms were stored in aliquots at
-808C. For immunofluorescence assay, chlamydial organisms were
used to infect HeLa cells grown on glass coverslips in 24-well plates.
The subconfluent HeLa cells were treated with DMEM containing 30
lg/mL of diethylaminoethyl (DEAE)-Dextran (Sigma, St. Louis, MO) for
10 minutes at 378C. After removal of DEAE-Dextan solution, chlamydial
organisms were added to the wells for 2 hours at 378C. The infected
cells were continuously cultured in DMEM with 10% FCS and 2 lg/mL
of cycloheximide (Sigma) for 30 (C. psittaci), 48 (C. trachomatis), or
72 (C. pneumoniae) hours before being processed for immunofluo-
rescence assay as described in the following section. Infection was also
carried out in tissue culture flasks for preparing whole cell lysates.
Immunofluorescence Assay
Antichlamydial antibodies in human sera were titrated using an
immunofluorescence assay (IFA) as previously described.14,26,30 Briefly,
HeLa cells infected with different species and serovars of chlamydia
were fixed with 2% paraformaldehyde and permeabilized with 2%
saponin. After blocking, human antisera was added to the chlamydia-
infected cell samples. The primary Ab binding was visualized with a
goat anti-human IgG conjugated with Cy3 (red; Jackson Immuno-
Research Laboratories, West Grove, PA), and DNA was labeled with
Hoechst dye (blue; Sigma-Aldrich, St. Louis, MO). The highest dilution
of a serum that still gave a positive reactivity was defined as the titer of
the given serum sample. Serum samples were serially diluted and the
appropriate dilutions were repeated multiple times based on the
results obtained from prior dilutions to obtain a more accurate titer for
each serum. The slides were observed under an Olympus AX70
fluorescence microscope equipped with multiple filter sets (Olympus,
Melville, NY), as described previously.14,30
Chlamydial Fusion Protein-arrayed Microplate
Enzyme-linked Immunosorbent Assay
Glutathione S-transferase (GST) fusion protein enzyme-linked immu-
nosorbent assay (ELISA) for detecting human antibody recognition of
chlamydial proteins was carried out as described previously.14,21,26 The
C. trachomatis proteome array was established based on the 908 open
reading frames (ORFs) encoded by C. trachomatis genital serovar D
genome and plasmid.26 Bacterial lysates containing individual chla-
mydial GST fusion proteins were added to 96-well microplates
precoated with glutathione (Pierce, Rockford, IL) at a 1:10 dilution in
PBS with a total volume of 200 lL/well. Lysates containing GST alone,
as negative, and GST-chlamydial protease/proteosomelike activity
factor (CPAF), as positive controls, were also included on each plate.
The plates were incubated overnight at 48C to allow GST fusion
proteins to bind to the plate-immobilized glutathione then blocked
with 2.5% milk in PBS and washing with PBST (PBS with 0.05% Tween
20; Sigma-Aldrich). After blocking, human serum samples were
preabsorbed with bacterial lysates containing GST alone at 48C
overnight, then incubated with glutathione beads (bioWorld, Dublin,
OH) for 1 hour at room temperature. This pretreatment can
significantly reduce background caused by nonspecific human
antibodies. The human antibody reactivity was detected with a goat
anti-human-IgG, IgA, IgM conjugated with horseradish peroxidase
(HRP; Jackson ImmunoResearch Laboratories) plus the substrate 2,20-
azino-bi(2-ethylbenzothiazoline-6-sulforic acid) diammonium salt
(ABTS; Sigma). The optical density (OD) was measured at 405 nm
using a microplate reader (Molecular Devices Corporation, Sunnyvale,
CA). To confirm the antibody binding specificity, all antisera were
further absorbed with lysates made from either HeLa cells alone or
Chlamydia-infected HeLa cells before reacting with the fusion protein-
coated plates. The antibody binding that remained positive after HeLa-
alone lysate absorption but significantly reduced by Chlamydia-HeLa
lysate absorption was considered true positive. In addition, the fusion
protein-based array assay is also routinely evaluated using normal
human sera similarly preabsorbed as described previously for further
excluding nonspecific binding.11,26,30,31 In this particular experiment,
we used the proteome to assay sera from eight health individuals and
no significant binding was detected between any of the 908 fusion
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proteins and the normal human sera (data not shown). These eight sera
displayed no significant reactivity with C. trachomatis–infected cells
(data not shown).
Data Analyses
Data were analyzed using SPSS v. 15.0 software (IBM, Chicago, IL) as
previously described.14,21 Student’s t-test was used to analyze the overall
mean differences in anti-Chlamydia antibody titers between the two
groups of patients or between different chlamydial organisms. Because
prior analyses of antibodies against some or all Chlamydia species in
trachoma patients showed no significant difference between case and
control groups,10,32 a two-tailed test seems to be more appropriate for
capturing all possible associations of antibody responses with a given
group. Because the antibody titers had large variations within a given
group, the serum titers were evaluated by ranges of less than 1:100
(Negative), 1:100 to 1:10,000 (Low), and greater than 1:10,000 (High).
Chi-squared and Fisher’s exact test were used to compare overall
antibodies to various chlamydial species and serovars.
For ELISA results, both Student’s t-test (for comparing quantitative
OD value data reflecting reactivity intensity) and Fisher’s exact test (for
comparing the number of antisera positively reacted with a given
antigen as reactivity frequency) were performed. When Student’s t-test
was used, the OD values after subtracting background from the same
plate were used. When Fisher’s exact test was used, a response was
determined positive when the OD value was equal to or greater than 2
SDs above the mean calculated from the same 96-well plate as
previously described.21 We accepted that there would be some false-
positive associations when screening antisera by the array and did not
adjust P values to account for multiple comparisons because the
normal methods of correcting P values and the general applicability of
adjusting for multiplicity of tests remain contentious among biostatis-
ticians.33–35 We did not estimate the power of the study because, in the
absence of other proteome array studies with sera from trachoma
endemic communities, it was not possible to estimate the size of the
expected differences or the number of antigens that may be
recognized. Unadjusted P values after multiple testing are presented
with the expected significant P value level after Bonferroni correction
presented in the footnotes.35 We calculated the potential number of
false-positive reactive antigen-antisera reactions at the 5% level
according to the method described by Stekel.34 At a P value less than
0.05, the number of potential false-positive antigens reactive with sera
is expected to be 0.05 · 19¼1 when the 19 antigens listed Table 3 are
analyzed statistically.
RESULTS
Patient Demographics
The study subject demographics information is listed in Table 1.
Sixty-one case control pairs were screened against the different
chlamydial species and serotypes used in the study (see
Supplementary Material, available at: http://www.iovs.org/
lookup/suppl/doi:10.1167/iovs.11–9212/-/DCSupplemental).
Fifty-nine of these individual serum samples were then screened
against the complete proteome array. Both groups had similar
age, sex, and ethnicity distributions. Fifty-seven percent of the
cases had TS/ TT in both eyes. Overall, 10% of the cases had
corneal opacity (CO) in at least one eye and phthisis (wasting)
was observed in the left eye of a single individual who also had
right eye TS/TT/CO. The ethnic groups from which the samples
were collected were consistent with main ethnicities present in
the Gambian districts and regions in which the study was
performed. All ocular swabs for these samples were positive for
human mitochondrial DNA. A single sample (L120) was positive
by C. trachomatis/Neisseria gonorrhoeae (CT/NG) Amplicor
(F. Hoffmann-La Roche Ltd., Basel, Switzerland) for current
ocular infection with C. trachomatis and this is consistent with
previous findings in The Gambia and elsewhere in Africa.22,36,37
Tests for current infection with other ocular pathogens were
not performed.
Both Trichiasis and Control Subjects Had High
Levels of Antibodies to Ocular C. trachomatis but
Not to Genital Serovars or C. psittaci Organisms
When antisera from 61 trichiasis subjects and 61 control
counterparts were reacted with organisms from different
chlamydial species, we found no statistically significant
TABLE 1. Patient Demographics
Individuals Screened
against Whole Organisms
Individuals Screened
against 908 Fusion Proteins
Group Cases Controls Cases Controls
Group Size 61 61 33 26
Age (range), y 60 (30–85) 55 (28–80) 59 (30–85) 52 (31–72)
Sex Male 19 19 12 7
Female 42 42 21 19
Ethnicity Mandinka 23 22 7 5
Jola 22 23 15 9
Manjago 14 15 9 12
Other 2 1 1 0
Pathology Uni TS/TT 22 0 14 0
þCO 4 0 1 0
Bi TS/TT 33 0 16 0
þCO 2 0 2 0
No. of CT positive (Amplicor result) 1 0 1 0
Sixty-one case control pairs were first screened against the different chlamydial species and serotypes as
described in the Materials and Methods section. Fifty-nine of these individual serum samples with relatively high
titers of antibodies against ocular serovars were further screened against 908 C. trachomatis fusion proteins. All
study groups displayed similar age, sex, and ethnicity distribution. The ethnic groups from which the samples
were collected were consistent with main ethnicities present in the Gambian districts and regions in which the
study was performed. A single sample (L120) was positive by CT/NG Amplicor for current ocular infection with
C. trachomatis. Tests for current infection with other ocular pathogens were not performed.
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difference in the titers of Chlamydia-specific antibodies
between the two groups (Table 2). Both groups developed
significantly higher titers of antibodies against C. trachomatis
ocular serovars A and B than serovar C (Table 3, P < 0.05),
suggesting that most of the study subjects had been infected
with serovars A and B but not C. Furthermore, a significantly
lower level of anti–C. trachomatis genital serovar D antibody
was detected in the 122 subjects (P < 0.01, compared with
anti-serovar A and B antibodies). Interestingly, in all 122
subjects, the highest titers of antibodies were anti–C. pneumo-
niae antibodies (higher than those of antiserovars A and B [P <
0.05]). The older ages of the study subjects may contribute to
the high titers of anti–C. pneumoniae antibodies as anti–C.
pneumoniae antibody titers are known to increase with age.
The anti–C. psittaci antibody levels were the lowest among all
chlamydial antibodies assayed (P < 0.01).
Mapping Chlamydial Immunodominant Antigens
in Individuals from a Trachoma-Endemic Area
Antisera from 59 individuals (33 trichiasis and 26 control sera)
with the highest titers of antibodies to C. trachomatis ocular
serovars were further reacted with 908 C. trachomatis
proteins. As shown, a total of 447 C. trachomatis-encoded
proteins were recognized by at least 1 of the 59 antisera (Figs.
1A, 1B, 1C) and 10 of these were positive in 50% or more
serum samples (Fig. 1D). These 10 antigens were designated as
immunodominant antigens. Interestingly, 5 of the 10 immuno-
dominant antigens are chlamydial proteins known to be
secreted into the host cell cytosol (CT858, pCT03, CT456,
CT694, and CT089). CT858, also called CPAF, is a serine
protease that is secreted into host cell cytosol via a sec-
dependent secretion pathway for manipulating host signaling
pathways.25,38–40 pCT03, also called Pgp3, is a plasmid-
encoded 28-kDa glycoprotein that is secreted into host cell
cytosol with unknown function and by unknown mecha-
nisms.27 CT456, known as translocated actin-recruiting phos-
phoprotein (TARP), is an effector molecule that is secreted into
host cell cytosol via a type III secretion pathway to facilitate
internalization of chlamydial elementary bodies (EBs) by
inducing actin polymerization.41,42 Interestingly, TARP appears
to be highly variable between different serovars of the same
species.11,43 CT694 is also a type III secretion effector that
modulates host cytoskeletal protein organization during EB
invasion,44 whereas CT089 or CopN is a type III secretion
pathway regulator.45 Among the remaining five immunodo-
minant antigens, CT143 is a hypothetical protein (HP),
whereas CT841 (FtsH) and CT806 (Ptr) are proteolytic
enzymes. CT240 is a recombinase (RecR), whereas CT517 is
the 50S ribosomal protein L24. Although many of these
immunodominant antigens overlap with those recognized by
patients who are urogenitally infected with C. trachomatis, the
sera from those with ocular exposure appear to selectively
target type III secretion effectors for antibody production,
suggesting that type III secretion activity may be more
prominent or a more important requirement in ocular
infection.
Identification of C. trachomatis Antigens
Differentially Recognized by Trichiasis or Control
Groups
Although most of the 447 antigens were recognized by the 59
antisera from both groups, filtering the results using statistical
analyses allowed us to identify 19 antigens that were associated
with differential reactivity and preferentially recognized by
individual groups (Table 4). A positive reaction between anT
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antigen and an antiserum was defined as a reaction with an OD
value equal to or above the mean plus 2 SDs derived from the
same microplate and used for calculating reactivity frequency
for a given antigen. Both the reactivity intensity (expressed as
absolute OD values) and reactivity frequency of an antigen
were statistically compared between triachiasis and normal
control groups. We found that sera from trichiasis patients
preferentially recognized four antigens. Antigens CT414,
CT667, and CT706 reacted with 30% of antisera from trichiasis
but none from the normal group. Antigen CT695 reacted with
61% of trichiasis but only 31% of normal group antisera (Fig. 2).
These four antigens were designated as pathology-associated
antigens. CT414 is a polymorphic outer membrane protein
designated as PmpC. CT667 is predicted to be a type III
secretion effector with unknown function. CT706 is an ATP-
dependent ClpP endopeptidase subunit. CT695 is a hypothet-
ical protein encoded by an ORF downstream of CT694, a
known type III secretion effector.
We also found that eight other antigens were preferentially
recognized by the normal control subject group with antigens
TABLE 3. Comparison of Antibodies against C. trachomatis Serovars A, B, C, and D; C. psittaci; and C. pneumoniae
Student’s t-Test (mean 6 SD) (n ¼ 122)
C. trachomatis
C. psittaci C. pneumoniae
Serovar A Serovar B Serovar C Serovar D 6BC AR39
C. trachomatis Serovar A (23,043.4 6 42,671.8) 1 0.5468 0.0088 0.0015 <0.0001 0.0567
Serovar B (20,162.3 6 30,988.4) 1 0.0123 0.0011 <0.0001 0.0039
Serovar C (11,892.6 6 18,755.8) 1 0.3446 0.0006 <0.0001
Serovar D (9810.7 6 15,422.8) 1 0.0067 <0.0001
C. psittaci 6BC (5485.2 6 8214.4) 1 <0.0001
C. pneumo-niae AR39 (32,759.0 6 36,340.3) 1
The antibodies against different chlamydial organisms were compared against each other using ANOVA (data not shown) and Student’s t-test.
The titers of anti–C. trachomatis serovar A or B antibodies in the 122 subjects are significantly higher than those of anti–C. trachomatis serovar C or
D, suggesting that these 122 individuals were mainly infected with ocular serovars A and B. The titers of antibodies against C. psittaci are the lowest,
whereas those of anti–C. pneumoniae antibodies were highest in the same 122 individuals, which both confirms that the titers of antibodies
detected in the assay were not caused by cross-reactivity and indicates that most of the 122 individuals were also coinfected with C. pneumoniae
but not C. psittaci.
FIGURE 1. Reactivity of 33 trichiasis and 26 normal control antisera with 908 ORFs of C. trachomatis. Each of the human antibodies (displayed
along the x-axis on top of each panel) after 1/1000 dilution was reacted with each of the 908 ORF GST fusion proteins (listed along the y-axis)
immobilized onto the 96-well microplates. Each colored bar represents a positive reactivity between a given ORF and an antiserum from trichiasis
(Tri, green) or normal control (Ctl, red) group. The results are expressed as OD readings obtained at the wavelength of 405 nm. Any reaction with
an OD ‡ meanþ 2 SDs calculated from the same plate is defined positive. The positive OD values are expressed as binding intensity in increasing
brightness of fluorescent color. The negative OD values are black. The 908 proteins are listed first in order of the ORFs from CT001 to pCT08 (A).
The 908 proteins were then reordered based on binding frequency by the trichiasis antisera from high (top) to low (bottom; see [B]). As indicated
on the right of the panel, a total of 447 ORFs were recognized by one or more antisera. (C) By visual inspection of the expanded view of the positive
antigens, the fusion proteins preferentially recognized by either trichiasis (green) or control (red) antisera were marked with brackets on the right of
the panel. (D) A total of 10 antigens were recognized by 50% or more of the 59 antisera.
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CT019, CT117, CT301, CT553, CT556, CT571, and CT709
reacting with 46% of antisera from normal but none from
trichiasis groups, and CT442 reacting with 35% of the normal
and 19% of the trichiasis antisera respectively. Most of these
proteins (CT019 [isoleucyl-tRNA synthetase or ileS], CT301
[probable serine/threonine kinase or pknD], CT553 [FMU/
SUN-related methyltransferase or fmu], CT709 [rod shape
determining protein MREB/HSP70 sugar kinase or mreB]) are
metabolic or modifying enzymes. CT117 and CT556 are
hypothetical proteins. CT571 is related to the general secretion
pathway (GspE), whereas CT442 is a cysteine-rich 15-kDa
outer membrane protein.
DISCUSSION
In the current study, we have demonstrated that the overall
antibody responses to chlamydial organisms are indistinguish-
able between individuals with or without trichiasis in
trachoma-endemic communities. Most individuals developed
high titers of antibodies against both C. trachomatis ocular
serovars A and B and C. pneumoniae organisms regardless of
the trichiasis status. It is likely that the antibodies detected
using C. trachomatis ocular serovar A and B organisms are
induced by ocular infection with C. trachomatis serovars A
and B in the study subjects and are not as a result of cross-
reactivity between C. pneumoniae–induced antibodies and C.
trachomatis ocular organisms. This is because these same
individuals displayed significantly lower levels of antibodies to
C. trachomatis ocular serovar C, genital serovar D, and C.
psittaci organisms, although the C. pneumoniae genome is
believed to share similar levels of homology with all C.
trachomatis serovars46,47 and an even higher level of
homology with C. psittaci.48,49 The observation that the
antiocular serovar A and B antibody titers were significantly
higher than that of antiserovar C antibodies suggests that C.
trachomatis ocular serovars A and B were most prevalent in
the communities from which our study subjects were
recruited. This is in keeping with the results of previous
studies in The Gambia, in which serovars A and B were found
to be predominant.50,51
To understand the molecular mechanisms of C. trachoma-
tis–induced ocular pathologies and to identify biomarkers for
trichiasis, we used a whole genome scale proteome array
established based on the 908 ORFs encoded by C. trachomatis
genital serovar D genome and plasmid26 to profile the antigen
specificities of the anti–C. trachomatis ocular serovar antibod-
ies in the study subjects. The C. trachomatis genital serovar
and ocular serovar genomes are highly conserved. For
example, there is 99.6% identity between serovars D and A.52
Major variations between the genital and ocular strain genomes
are in the regions containing genes coding for tryptophan
synthase A/B,47 cytotoxins,53 TARP,52 and polymorphic mem-
brane proteins or Pmps.52 In most cases, reported nucleic acid
polymorphisms result in silent mutations or variations that lead
to ocular serovar proteins with shorter sequences or loss of
function. No ocular serovar–unique proteins have been
identified. Thus, the genital serovar D proteins can be used
to detect antibodies that recognize the vast majority of antigens
from the ocular serovars. We recognize that the serovar D
proteins-based proteome array has some limitations and would
not detect antibodies that react only with ocular strain–specific
epitopes; however, this deficiency should not significantly alter
the major findings in the current study.
Among the 908 C. trachomatis proteins measured, 447
antigens were recognized by at least one of the human antisera
and 10 antigens were recognized by 50% or more antisera, the
latter thus designated as immunodominant antigens. Interest-
ingly, 5 of the 10 immunodominant antigens are proteins
known to be secreted into host cell cytoplasm,25,27,41,45
suggesting that chlamydial secretion proteins have enhanced
immunogenicity. These immunodominant antigens have also
TABLE 4. Antigens Preferentially Recognized by Trichiasis or Control Subjects
ORFs
Trichiasis (n ¼ 33) Control (n ¼ 26) P Value
Antigen AffiliationX 6 SD (Freq) X 6 SD (Freq) t-Test Fisher’s
CT695 0.281 6 0.300 (61%) 0.189 6 0.157 (31%) 0.163 0.016 Pathology-associated
CT706 0.096 6 0.165 (18%) 0.027 6 0.043 (0%) 0.044 0.024
CT667 0.066 6 0.084 (6%) 0.021 6 0.034 (0%) 0.012 0.201
CT414 0.055 6 0.088 (6%) 0.016 6 0.025 (0%) 0.034 0.201
CT019 0.059 6 0.058 (0%) 0.075 6 0.075 (15%) 0.337 0.019 Protection-associated
CT571 0.044 6 0.048 (0%) 0.075 6 0.121 (15%) 0.185 0.019
CT117 0.032 6 0.049 (0%) 0.075 6 0.211 (12%) 0.256 0.045
CT301 0.024 6 0.036 (0%) 0.065 6 0.124 (12%) 0.077 0.045
CT553 0.029 6 0.030 (0%) 0.139 6 0.398 (12%) 0.123 0.045
CT556 0.025 6 0.041 (0%) 0.068 6 0.116 (12%) 0.054 0.045
CT709 0.061 6 0.053 (0%) 0.101 6 0.202 (12%) 0.281 0.045
CT442 0.114 6 0.167 (18%) 0.317 6 0.503 (35%) 0.034 0.087
CT656 0.003 6 0.007 (0%) 0.019 6 0.036 (0%) 0.012 NA The reactivity is too low to be
biologically significant.CT404 0.028 6 0.031 (0%) 0.012 6 0.016 (0%) 0.026 NA
CT279 0.008 6 0.018 (0%) 0.023 6 0.030 (0%) 0.029 NA
CT368 0.022 6 0.025 (0%) 0.039 6 0.039 (0%) 0.031 NA
CT651 0.043 6 0.053 (0%) 0.019 6 0.023 (0%) 0.033 NA
CT817 0.010 6 0.021 (0%) 0.025 6 0.031 (0%) 0.037 NA
CT864 0.009 6 0.020 (0%) 0.023 6 0.030 (0%) 0.049 NA
When both the reactivity intensity (comparison of raw OD values using Student’s t-test) and frequency (Fisher’s exact test) listed in Figure 2
were statistically compared between the trichiasis and control groups, a total of 19 antigens (as listed in the first column) showed significant
differences in either reactivity intensity or frequency or both between the two groups. However, the reactivity of seven antigens is too low to be
biologically significant (bottom portion). Among the remaining 12 antigens, 4 were preferentially recognized by sera from the trichiasis group (top
portion) and were designated as pathology-associated antigens, whereas 8 were recognized by the normal control group (middle portion), thus
designated as protection-associated antigens.
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been shown to be preferentially recognized by individuals
infected with C. trachomatis urogenital strains,26 suggesting
that these proteins may be essential for C. trachomatis
infection in humans, even though some of these proteins are
not highly expressed in chlamydial EBs.25,26
Importantly, the proteome array has also allowed us to
identify four antigens that were preferentially recognized by
sera from the trichiasis group, thus these were designated as
pathology-associated antigens. The four pathology-associated
antigens are CT414, CT667, CT706, and CT695. Expression of
these antigens by Chlamydia and immune responses to these
antigens during chlamydial infection may be biomarkers
associated with the trichiasis phenotype or could be mecha-
nistically contributing to ocular pathologies. In women with
tubal factor infertility, chlamydial anti-HSP60 and OmcB
antibodies have been identified as biomarkers.14,21 Moreover,
immune responses to HSP60 have been implicated in the
pathogenesis of tubal damage. Anti-chlamydial HSP60 antibod-
ies may cross-react with host HSP6019,20 or anti-HSP60 T-cell
responses may be directed against host tissues.16,17 Surprising-
ly, neither the chaperon HSP60 nor the outer membrane
protein OmcB was identified by trichiasis antisera reactivity in
our current study subjects. Instead, another chaperone with
proteolytic activity, CT706 (an ATP-dependent ClpP endopep-
tidase subunit) and another outer membrane protein CT414
(PmpC) plus two putative type III secretion effectors (CT667
and CT695) were significantly associated with trichiasis. At
present, it remains unknown whether these four proteins and
immune responses induced by these antigens can mechanis-
tically contribute to ocular pathology during C. trachomatis
infection.
Equally important, the same proteome array has also
allowed us to identify eight antigens that were preferentially
recognized by sera from the control group, thus designated as
protection-associated antigens. The eight protection antigens
are CT019, CT117, CT301, CT442, CT553, CT556, CT571, and
CT709. Most of these proteins are highly conserved metabolic
or modifying enzymes (CT019, CT301, CT553, CT709) or
related to the general secretion pathway (CT571). The
remaining three antigens are hypothetical proteins unique to
Chlamydia. CT117, consisting of 104 amino acids (aa) with a
bilobal hydrophobic region and a pI of 8.21, is a putative
inclusion membrane protein designated as IncF,54,55 and IncF is
highly immunogenic in women urogenitally infected with C.
FIGURE 2. Distribution of the reactivity patterns of 12 C. trachomatis antigens with 59 patient antisera. Number of trichiasis (TT) and control (NC)
antisera that positively (POS) reacted with each of the 12 antigens (listed at both top and bottom of the figure) is summarized in (A). The reactivity
distribution patterns of the 12 antigens with 33 trichiasis and 26 control antisera are revealed in (B) and (C), respectively. Each horizontal bar
indicates a positive reactivity. The pathology-associated antigens CT706, CT667, and CT414 reacted with 10 unique antisera from the trichiasis
group (each marked with a star, representing 30% of the total trichiasis antisera) but failed to react with any normal control antisera (100%
specificity), whereas the protection-associated antigens CT019, CT571, CT117, CT301, CT553, CT556, and CT709 reacted with 12 of the normal
antisera (each unique antiserum was marked with a star, representing 46% of the total control antisera) without reacting with any of the trichiasis
antisera. However, the pathology-associated antigen CT695 and the protection-associated antigen CT442 reacted with both TT and NC antisera.
Nevertheless, CT695 was statistically significantly recognized by TT whereas CT442 by NC respectively as revealed in Table 3.
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trachomatis.30,31 CT556, consisting of 159 aa with a putative
transmembrane domain at its C-terminus and an acidic pI of
4.95, shares a low level of homology with a thiol:disulfide
interchange protein DsbC of Pseudomonas aeruginosa.56
CT442 has been characterized as a cysteine-rich 15-kDa outer
membrane protein, designated as CrpA.57 CT442 is predicted
to localize in the inclusion membrane54; moreover, it contains
a murine CD8þ T-cell epitope that can elicit partial protective
immunity to subsequent challenge with C. trachomatis.58
These three antigens (CT117, 442, and 556) appear to be
suitable candidates for vaccine development, as they possess
properties ideal for constructing an antitrachoma subunit
vaccine: each are Chlamydia-specific, likely localized in
chlamydial organism or inclusion membrane, immunogenic
in humans, and able to induce protective immunity. More than
half a century ago, vaccination with formalin-fixed whole
chlamydial organisms not only failed to induce long-lasting
protective immunity against trachoma but also exacerbated
ocular pathologies when some immunized children were
exposed to natural infection.59–62 These early observations
might suggest that the formalin-fixed organisms not only had
their protective antigen conformation altered by formalin
fixation but also carried pathogenic antigens. Thus, a subunit
vaccine by selecting protective antigens in their native
conformation and excluding the pathogenic determinants
may represent a promising approach for development of a
vaccine to prevent trachomatous disease. Further evaluation of
these Chlamydia-specific protection-associated antigens for
their ability to induce protective immunity in an appropriate
model system should provide important information for
developing a subunit vaccine against C. trachomatis ocular
infection and C. trachomatis–induced ocular diseases.
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